Cervical cancer control in HIV-infected women

Past, present and future

Rahel G Ghebre, Surbhi Grover, Melody J. Xu, Linus T. Chuang, Hannah Simonds

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalGynecologic Oncology Reports
Volume21
DOIs
StatePublished - Aug 1 2017

Fingerprint

Uterine Cervical Neoplasms
HIV
Africa South of the Sahara
Papillomavirus Vaccines
Mortality
Opportunistic Infections
Conservation of Natural Resources
Early Detection of Cancer
Early Diagnosis
Acquired Immunodeficiency Syndrome
Survival
Neoplasms
Therapeutics

Keywords

  • Cervical cancer
  • Cervical cancer screening
  • Chemoradiation therapy
  • Human immunodeficiency virus (HIV)
  • Limited resource setting

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Cervical cancer control in HIV-infected women : Past, present and future. / Ghebre, Rahel G; Grover, Surbhi; Xu, Melody J.; Chuang, Linus T.; Simonds, Hannah.

In: Gynecologic Oncology Reports, Vol. 21, 01.08.2017, p. 101-108.

Research output: Contribution to journalReview article

Ghebre, Rahel G ; Grover, Surbhi ; Xu, Melody J. ; Chuang, Linus T. ; Simonds, Hannah. / Cervical cancer control in HIV-infected women : Past, present and future. In: Gynecologic Oncology Reports. 2017 ; Vol. 21. pp. 101-108.
@article{0e1d908c4ce04aaf96a566c2330d035a,
title = "Cervical cancer control in HIV-infected women: Past, present and future",
abstract = "Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.",
keywords = "Cervical cancer, Cervical cancer screening, Chemoradiation therapy, Human immunodeficiency virus (HIV), Limited resource setting",
author = "Ghebre, {Rahel G} and Surbhi Grover and Xu, {Melody J.} and Chuang, {Linus T.} and Hannah Simonds",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.gore.2017.07.009",
language = "English (US)",
volume = "21",
pages = "101--108",
journal = "Gynecologic Oncology Reports",
issn = "2211-338X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Cervical cancer control in HIV-infected women

T2 - Past, present and future

AU - Ghebre, Rahel G

AU - Grover, Surbhi

AU - Xu, Melody J.

AU - Chuang, Linus T.

AU - Simonds, Hannah

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.

AB - Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality. In line with 2030 Sustainable Development Goals to reduce mortality from non-communicable diseases, increased efforts need to focus on high burden countries within sub-Saharan Africa (SSA). Despite limitations of resources in SSA, opportunities exist to improve cancer control. This article reviews advancements in cervical cancer control in HIV-positive women.

KW - Cervical cancer

KW - Cervical cancer screening

KW - Chemoradiation therapy

KW - Human immunodeficiency virus (HIV)

KW - Limited resource setting

UR - http://www.scopus.com/inward/record.url?scp=85027531675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027531675&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2017.07.009

DO - 10.1016/j.gore.2017.07.009

M3 - Review article

VL - 21

SP - 101

EP - 108

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

SN - 2211-338X

ER -